Rozanolixizumab has become the first targeted therapy to be approved for the treatment of refractory generalised myasthenia gravis and will be eligible for reimbursement via NHS England. Read more
The SMC has released negative guidance for the medicine Zilucoplan. Learn more about this process and next steps. Read more
Learn more about this treatment method which is being explored in myasthenia gravis patients. Read more
Find out more about our successful appeal against NICE's decision to issue negative guidance for the drug zilucoplan. Read more
Read more about our stance on NICE's decision to release negative final draft guidance for zilucoplan, a new medicine for myasthenia gravis. Read more
Read our statement on the disappointing news that efgartigimod will not be made available to patients in England on the NHS. Read more
NICE have released negative guidance for efgartigimod after appeal and zilucoplan after a second committee meeting. We need the patient community to engage with decision makers and raise our collective voice against these decisions. Read more
Find out about treatments currently in development.... Read more
Learn more about Zilucoplan (Zilbrysq) Read more
Learn more about Rozanolixizumab (Rystiggo) Read more
Myaware and MDUK sent a joint letter to NICE and the related companies about targeted therapeutics in the myasthenia community. Read more about our letter and petition here Read more
Myaware are continuing to engage with the relevant companies linked to the Propantheline Bromide shortage. In the meantime, we have some guidance regarding alternatives and importers for unlicensed propantheline. Read more
The appraisal for assessment of the use of Ravulizumab on the NHS has been withdrawn by the company. A third committee meeting to assess Efgartigimod has been scheduled for May 2024 following the release of further draft guidance. Myaware are looking for members to get involved and share their views with NICE to emphasise the importance of new treatments to the myasthenia community. Read more
As of October 2023, NICE have released initial guidance not recommending the use of Ravulizumab on the NHS. Click here to find out more about what this draft guidance entails and how myaware members can provide their input. Read more
The Medicines and Healthcare products Regulatory Agency (MHRA) have released new guidance following a small number of reports of myasthenic aggravation in patients taking statins. Read more
Guidance not recommending the use of Efgartigimod on the NHS. Click here to find out more... Read more
Learn more about Rituximab (MabThera). Read more
Learn more about Ravulizumab (Ultomiris). Read more
Learn more about Mycophenolate (Cellcept/Myfenax). Read more
Learn more about Neostigmine bromide (Bloxiverz). Read more
Learn more about Pyridostigmine (Mestinon). Read more
Find out about the Early Access to Medicines Scheme. Read more
Learn more about Azathioprine (Imuran). Read more
Learn more about Efgartigimod (Vygart). Read more